文献速递消化系统肿瘤

复发性胰腺癌的进化起源

The Evolutionary Origins of Recurrent Pancreatic Cancer.
PubMed 文献 · Cancer Discov · 2020-03-19

该研究对10例切除的原发胰腺癌及匹配的胰内复发或远处转移灶进行全外显子或靶向测序,发现复发灶突变负荷增高,富集MAPK/ERK和PI3K-AKT通路激活相关改变,克隆起源可为单克隆或多克隆。治疗诱导的遗传瓶颈导致驱动基因改变的亚克隆异质性,部分源于转移灶间种植。1例被认为复发者实为独立第二原发肿瘤。

要点

  • 复发胰腺癌突变负荷高于未治疗原发灶
  • 复发灶富集MAPK/ERK和PI3K-AKT通路激活改变
  • 复发可呈单克隆或多克隆起源,存在转移灶间种植

核心结论

  • 复发性胰腺癌具有独特的基因组景观、转移灶间遗传异质性、多样克隆起源和高于未治疗疾病的突变负荷。

研究设计与样本

  • 对10例切除的原发胰腺癌及匹配的胰内复发或远处转移灶进行全外显子或靶向测序。

主要发现

  • 辅助或一线铂类治疗后复发对应突变负荷增加。
  • 复发灶富集预测激活MAPK/ERK和PI3K-AKT信号的遗传改变。
  • 复发灶呈单克隆或多克隆起源,治疗诱导的遗传瓶颈导致驱动基因改变亚克隆异质性,部分因转移灶间种植。
  • 1例被认为复发者实为独立第二原发肿瘤。

临床怎么用

  • 常规治疗后采样可能对复发性胰腺癌的管理有价值。

局限性

  • 样本量较小(10例),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Surgery is the only curative option for stage I/II pancreatic cancer; nonetheless, most patients will experience a recurrence after surgery and die of their disease. To identify novel opportunities for management of recurrent pancreatic cancer, we performed whole-exome or targeted sequencing of 10 resected primary cancers and matched intrapancreatic recurrences or distant metastases. We identified that recurrent disease after adjuvant or first-line platinum therapy corresponds to an increased mutational burden. Recurrent disease is enriched for genetic alterations predicted to activate MAPK/ERK and PI3K-AKT signaling and develops from a monophyletic or polyphyletic origin. Treatment-induced genetic bottlenecks lead to a modified genetic landscape and subclonal heterogeneity for driver gene alterations in part due to intermetastatic seeding. In 1 patient what was believed to be recurrent disease was an independent (second) primary tumor. These findings suggest routine post-treatment sampling may have value in the management of recurrent pancreatic cancer. SIGNIFICANCE: The biological features or clinical vulnerabilities of recurrent pancreatic cancer after pancreaticoduodenectomy are unknown. Using whole-exome sequencing we find that recurrent disease has a distinct genomic landscape, intermetastatic genetic heterogeneity, diverse clonal origins, and higher mutational burden than found for treatment-naïve disease.See related commentary by Bednar and Pasca di Magliano, p. 762.This article is highlighted in the In This Issue feature, p. 747.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Sakamoto H, Attiyeh MA, Gerold JM, et al. The Evolutionary Origins of Recurrent Pancreatic Cancer. Cancer Discov. 2020. PMID: 32193223. doi:10.1158/2159-8290.CD-19-1508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。